These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37476076)

  • 1. Long-term Safety and Tolerability of Omadacycline for the Treatment of
    Mingora CM; Bullington W; Faasuamalie PE; Levin A; Porter G; Stadnick R; Varley CD; Addrizzo-Harris D; Daley CL; Olivier KN; Winthrop KL; Dorman SE; Flume PA
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad335. PubMed ID: 37476076
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Brown-Elliott BA; Wallace RJ
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omadacycline for the Treatment of
    Pearson JC; Dionne B; Richterman A; Vidal SJ; Weiss Z; Velásquez GE; Marty FM; Sax PE; Yawetz S
    Open Forum Infect Dis; 2020 Oct; 7(10):ofaa415. PubMed ID: 33094118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes.
    El Ghali A; Morrisette T; Alosaimy S; Lucas K; Tupayachi-Ortiz MG; Vemula R; Wadle C; Philley JV; Mejia-Chew C; Hamad Y; Stevens RW; Zeuli JD; Webb AJ; Fiske CT; Simonyan A; Cimino CL; Mammadova M; Umana VE; Hasbun R; Butt S; Molina KC; Thomas M; Kaip EA; Bouchard J; Gore TW; Howard C; Cabanilla MG; Holger DJ; Frens JJ; Barger M; Ong A; Cohen KA; Rybak MJ
    Antimicrob Agents Chemother; 2023 Oct; 67(10):e0082423. PubMed ID: 37768312
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Zhang T; Du J; Dong L; Wang F; Zhao L; Jia J; Wang C; Cheng M; Yu X; Huang H
    Microbiol Spectr; 2023 Feb; 11(1):e0323822. PubMed ID: 36475850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use.
    Rizzo AR; Moniri NH
    BMC Infect Dis; 2022 Nov; 22(1):874. PubMed ID: 36419143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates
    Nicklas DA; Maggioncalda EC; Story-Roller E; Eichelman B; Tabor C; Serio AW; Keepers TR; Chitra S; Lamichhane G
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0170421. PubMed ID: 34662184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omadacycline therapy for Mycobacterium abscessus species infections.
    Ingram PR; Jones EE; Allen B; Murray RJ; Keehner TJ; Whitmore TJ
    Intern Med J; 2023 Dec; 53(12):2257-2263. PubMed ID: 36917124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary, Real-world, Multicenter Experience With Omadacycline for
    Morrisette T; Alosaimy S; Philley JV; Wadle C; Howard C; Webb AJ; Veve MP; Barger ML; Bouchard J; Gore TW; Lagnf AM; Ansari I; Mejia-Chew C; Cohen KA; Rybak MJ
    Open Forum Infect Dis; 2021 Feb; 8(2):ofab002. PubMed ID: 33628856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.
    Shin SH; Jhun BW; Kim SY; Choe J; Jeon K; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104265
    [No Abstract]   [Full Text] [Related]  

  • 11. Omadacycline in first-line combination therapy for pulmonary Mycobacterium abscessus infection: a case series.
    Duah M; Beshay M
    Int J Infect Dis; 2022 Sep; 122():953-956. PubMed ID: 35798234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of omadacycline against intracellular
    Jahanbakhsh S; Howland J; Ndayishimiye Uwineza MO; Thwaites MT; Pillar CM; Serio AW; Anastasiou DM; Hufnagel DA
    JAC Antimicrob Resist; 2023 Oct; 5(5):dlad104. PubMed ID: 37720564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus.
    Bax HI; de Vogel CP; Mouton JW; de Steenwinkel JEM
    J Antimicrob Chemother; 2019 Oct; 74(10):2930-2933. PubMed ID: 31236595
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Kaushik A; Ammerman NC; Martins O; Parrish NM; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease.
    Rimal B; Nicklas DA; Panthi CM; Lippincott CK; Belz DC; Ignatius EH; Deck DH; Serio AW; Lamichhane G
    mSphere; 2023 Apr; 8(2):e0066522. PubMed ID: 36912629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease.
    Lyu J; Kim BJ; Kim BJ; Song JW; Choi CM; Oh YM; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2014 Nov; 108(11):1706-12. PubMed ID: 25245792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.
    Martiniano SL; Wagner BD; Levin A; Nick JA; Sagel SD; Daley CL
    Chest; 2017 Oct; 152(4):800-809. PubMed ID: 28483608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease.
    Singh S; Wang JY; Heysell SK; McShane PJ; Wadle C; Shankar P; Huang HL; Pasipanodya J; Boorgula GD; Philley JV; Gumbo T; Srivastava S
    Int J Antimicrob Agents; 2023 Jul; 62(1):106847. PubMed ID: 37187338
    [TBL] [